ICUI:NSD-ICU Medical Inc (USD)

COMMON STOCK | Medical Instruments & Supplies |

Last Closing

USD 174.81

Change

-3.20 (-1.80)%

Market Cap

USD 4.17B

Volume

0.63M

Analyst Target

USD 216.33
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps. The company provides IV therapy and diluents, such as sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation solutions comprising sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. It offers infusion pumps under the Plum 360 and Plum Duo brands; ambulatory and syringe infusion hardware products; IV mediation safety software, including ICU Medical MedNet, an enterprise-class medication management platform; LifeShield and PharmGuard medication infusion safety software; hemodynamic monitoring products; anesthesia systems and devices, breathing circuits, ventilation, respiratory, and specialty airway products; temperature management solutions; anesthesia/pain management trays and components; and professional services. The company's customers include acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, including outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is based in San Clemente, California.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-11-13 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap
ISRG Intuitive Surgical Inc

-0.38 (-0.07%)

USD 180.35B
COO The Cooper Companies, Inc. Com..

-0.12 (-0.12%)

USD 20.95B
HOLX Hologic Inc

-0.58 (-0.73%)

USD 19.12B
ALGN Align Technology Inc

-4.06 (-1.85%)

USD 16.05B
RGEN Repligen Corporation

+1.88 (+1.27%)

USD 7.52B
MMSI Merit Medical Systems Inc

-2.56 (-2.46%)

USD 5.76B
XRAY Dentsply Sirona Inc

-0.42 (-2.36%)

USD 4.76B
AZTA Azenta Inc

-1.48 (-3.22%)

USD 2.25B
LMAT LeMaitre Vascular Inc

-0.69 (-0.67%)

USD 2.00B
ATRC AtriCure Inc

-0.43 (-1.17%)

USD 1.76B

ETFs Containing ICUI

PRFZ Invesco FTSE RAFI US 1500.. 0.00 % 0.39 %

-0.43 (-0.67%)

USD 2.56B
PSCH Invesco S&P SmallCap Heal.. 0.00 % 0.29 %

-0.51 (-0.67%)

USD 0.18B
ISMD Inspire Small/Mid Cap Imp.. 0.00 % 0.62 %

-0.27 (-0.67%)

USD 0.19B

Market Performance

  Market Performance vs. Industry/Classification (Medical Instruments & Supplies) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 75.27% 93% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 75.27% 93% A 91% A-
Trailing 12 Months  
Capital Gain 97.55% 93% A 91% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 97.55% 91% A- 90% A-
Trailing 5 Years  
Capital Gain 0.21% 59% D- 50% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 0.21% 59% D- 42% F
Average Annual (5 Year Horizon)  
Capital Gain -9.59% 23% F 22% F
Dividend Return -9.59% 23% F 21% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 23.32% 91% A- 71% C-
Risk Adjusted Return -41.14% 21% F 16% F
Market Capitalization 4.17B 82% B 87% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector